未登录

C

Chunjing Wu

Miami VA Healthcare System

H指数:20

被引数:1,299

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Systemic immunometabolic profiling classifies cisplatin sensitivity states using interpretable machine learning

系统性免疫代谢谱分析利用可解释机器学习方法对顺铂敏感性状态进行分类

IF4.1

2026-02-170

OAAI

Orthotopic Models Using New, Murine Lung Adenocarcinoma Cell Lines Simulate Human Non-Small Cell Lung Cancer Treated with Immunotherapy

使用新的鼠肺腺癌细胞系的原位模型模拟了用免疫疗法治疗的人类非小细胞肺癌

IF5.2

2024-06-280

OAAI

Targeting of metabolic reprogramming in lung cancer by utilizing patient-derived organoid tissue for precision medicine

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Can serum exosomal content predict response to immunotherapy in hepatocellular carcinoma

CANCER RESEARCH

IF16.6

2024-03-220

PRE

A platform of ADAPTive scaffolds: development of CDR-H3 β-hairpin mimics into covalent inhibitors of the PD1/PDL1 immune checkpoint

RSC CHEMICAL BIOLOGY

IF3.1

2024-01-010

OAAI

Exploiting the kynurenine pathway to combat platinum-resistant non-small cell lung cancer (NSCLC)

EUROPEAN RESPIRATORY JOURNAL

IF21

2023-10-270

PRE

Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer

CANCER & METABOLISM

IF5.3

2023-05-2411

OAAI

Targeting IDO1 and TDO2 is crucial for the modulation of immune effector in platinum resistant non-small cell lung cancer

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Can exosomal cargoes predict checkpoint inhibitor response in melanoma, and can we overcome drug resistance

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer

MOLECULAR CANCER RESEARCH

IF4.7

2020-01-0239

OAAI

Surviving skills in melanoma cells: An important consideration to both targeted and immunological approach in the treatment of melanoma

CANCER RESEARCH

IF16.6

2019-07-010

PRE

Kynurenine - Aryl hydrocarbon receptor axis: A crucial modulator of immunometabolism in cisplatin resistant lung cancer

CANCER RESEARCH

IF16.6

2019-07-011

PRE

Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma

pembrolizumab和循环生物标志物预测晚期不可切除肝细胞癌抗癌反应的2期研究

IF5.1

2019-06-28139

OAAI

Relationship of argininosuccinate synthetase (ASS) and PD-L1 expression in arginine enriched or depleted environment in melanoma

CANCER RESEARCH

IF16.6

2018-07-010

PRE

Targeting kynurenine pathway for the treatment of cisplatin-resistant lung cancer

CANCER RESEARCH

IF16.6

2018-07-010

PRE

The dual effects of a novel peptibody on angiogenesis inhibition and M2 macrophage polarization on sarcoma

IF10.1

2018-03-0118

PREAI

Degradation of AMPK-1 sensitizes BRAF inhibitor-resistant melanoma cells to arginine deprivation

MOLECULAR ONCOLOGY

IF4.5

2017-11-1621

OAAI

Novel approach to circumvent cisplatin resistant lung cancer by targeting metabolism

CANCER RESEARCH

IF16.6

2017-07-010

PRE

The relationship of Procollagen alpha 1 type 1 (Col1A1) / DDR2 signaling in malignant glioma and sensitivity to STAT 3/5 inhibitor

CANCER RESEARCH

IF16.6

2016-07-151

PRE

BRAF inhibitor resistance reprograms metabolic and survival pathways to sensitize melanoma cells to arginine deprivation

CANCER RESEARCH

IF16.6

2016-07-150

PRE